doi: 10.1016/j.atherosclerosis.2015.10.091 91 NaghipourS.CoxA
Eligibility and Supervised Use Saxenda is particularly recommended for individuals with a Body Mass Index (BMI) exceeding 30 kg/m, or for those with a BMI over 27 kg/m accompanied by chronic conditions such as hypertension, type 2 diabetes, or hyperlipidemia
This allows very fine dose adjustments, but it also introduces measurement and sterility risks
The differences in weight loss between SELECT and STEP I highlight the crucial role of comprehensive care beyond medication
Concurrent medications can interfere with weight loss efforts
FDA can consider the committees votes, the discussion, the staff analysis, and public comments as it determines the next regulatory step